Simultaneous Estimation of Ciprofloxacin hydrochloride and Dexamethasone sodium phosphate in Ophthalmic Formulations

The simultaneous estimation of multiple active pharmaceutical ingredients (APIs) in combined dosage forms has become increasingly significant in the pharmaceutical industry, especially for formulations intended for topical applications such as ophthalmic preparations. This review article focuses on the analytical methodologies developed for the simultaneous estimation of Ciprofloxacin hydrochloride (CIP) and Dexamethasone sodium phosphate (DEX) in ophthalmic formulations. CIP, a broad-spectrum fluoroquinolone antibiotic, and DEX, a potent corticosteroid, are often co-formulated to provide both antibacterial and anti-inflammatory effects in the treatment of ocular infections. However, the co-existence of these chemically distinct compounds poses analytical challenges due to differences in their physicochemical properties. Various analytical techniques have been explored for the simultaneous estimation of CIP and DEX, including UV-Visible spectrophotometry, high-performance liquid chromatography (HPLC), and derivative spectroscopic methods. Among these, HPLC has been widely preferred due to its high sensitivity, selectivity, and accuracy. Validation of these methods, according to US FDA guidelines, ensures reliability in terms of parameters like linearity, precision, accuracy, robustness, and specificity. Spectrophotometric techniques, while simpler and cost-effective, often suffer from overlapping absorption spectra, requiring mathematical correction methods or derivative approaches.